LUNG · CIK 1127537
What Pulmonx Corp. told the SEC could break it.
Pulmonx's disclosures share one through-line: concentration at nearly every point of its business. It depends on a single product, the Zephyr Endobronchial Valve, which can only be marketed for limited indications, and it remains unprofitable, with a $54.0M net loss in 2025 and a $521.6M accumulated deficit. That single product, in turn, is built from single-source critical components with few alternatives and manufactured entirely at one Redwood City, California facility — so a supplier failure or a disruption at that one site would halt output. And substantially all of its revenue runs through third-party payors, with roughly 75% of potential patients on Medicare, leaving coverage and reimbursement decisions central to its commercial success.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Other disclosures
- single-product dependence (Zephyr Valve); recurring net losseshigh
Pulmonx relies on a single product, the Zephyr Endobronchial Valve (marketable only for limited indications), for most revenue, and remains unprofitable ($54.0M net loss in 2025, $521.6M accumulated deficit).
“We currently rely on a single product, the Zephyr Endobronchial Valve (“Zephyr Valve”), which can only be marketed for limited indications, and if we are not successful in commercializing the Zephyr Valve, our business, financial condition and results of operations will be negatively affected;”
SEC filing →As of 2026
Sole-source dependency
- single-source suppliers for critical components, sub-assemblies and materialshigh
Pulmonx relies on single-source suppliers for critical components, sub-assemblies and materials with no or few alternatives, and fully outsources AeriSeal manufacturing to a contract manufacturer — concentrating supply risk.
“The Company relies on single source suppliers for the components, sub-assemblies and materials for its products. These components, sub-assemblies and materials are critical and there are no or relatively few alternative sources of supply.”
SEC filing →As of 2026
Geographic concentration
- all products manufactured at a single Redwood City, CA facilitymedium
Pulmonx manufactures all of its products at a single facility in Redwood City, California (production, QC and storage), so disruption at that one site would halt output.
“We manufacture all our products at our headquarters located in Redwood City, California. This facility supports production and distribution operations, including manufacturing, quality control, raw material and finished goods storage.”
SEC filing →As of 2026
Regulatory & policy
- third-party reimbursement / coverage dependence (≈75% Medicare patients)low
Pulmonx derives substantially all revenue from products reimbursed by third-party payors (roughly 75% of potential patients are Medicare beneficiaries); inadequate coverage/reimbursement or high patient out-of-pocket costs could severely hinder commercial success.
“If we are unable to achieve and maintain adequate levels of coverage or reimbursement for our solution, or any future products we may seek to commercialize, or if patients are left with significant out-of-pocket costs, our commercial success may be severely hindered.”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch